title: Antioxidant defense against antidepressants in C6 and 1321N1 cells.
abstract: The effects of pretreatment with the antioxidants reduced glutathione (GSH), ascorbate (ASC), Trolox (TROL), and combined ascorbate and Trolox (ASC/TROL) exposure on the acute (24 h) toxicities (EC50 value) of the antidepressants amitriptyline, imipramine (tricyclic antidepressants), fluoxetine (a selective serotonin reuptake inhibitor; SSRI), and tranylcypromine (a monoamine oxidase inhibitor; MAOI) were determined in the rat (C6) glioma and human (1321N1) astrocytoma cell lines using the neutral red uptake assay. The effects of pretreatment with buthionine-[S, R]-sulfoximine (BSO), and manipulation of intracellular cyclic AMP (cAMP) using isoproterenol (beta-receptor agonist), 3-isobutyl-1-methylxanthine (IBMX; a phosphodiesterase inhibitor), and dibutyryl cyclic AMP (dBcAMP; cAMP analogue) on antidepressant toxicity were also determined. Protective responses were observed after antioxidant treatments and manipulation of cAMP in both C6 cells pretreated with dBcAMP (+dBcAMP) and 1321N1 cells not pretreated with dBcAMP (-dBcAMP), with a few exceptions in 1321N1 cells (-dBcAMP). Some protective responses occurred in C6 cells (-dBcAMP) and 1321N1 cells (+dBcAMP) after isoproterenol and combined IBMX/isoproterenol pretreatment but not after just IBMX pretreatment. Pretreatment with BSO enhanced toxicity with the exception of fluoxetine. The antidepressants caused increases in intracellular GSH in the C6 cells at subcytotoxic concentrations, with decreases in GSH occurring at higher concentrations. Cytotoxicity of the antidepressants may be partly mediated through oxidative stress with alterations in signal transduction pathways.
authors.affiliation: Department of Biological Sciences, University of Salford, M5 4WT, Salford, UK.
authors.forename: N D
authors.initials: ND
authors.lastname: Slamon
authors.forename: V W
authors.initials: VW
authors.lastname: Pentreath
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000633:toxicity*; D000963:Antimetabolites / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D001254:Astrocytoma; D003994:Bucladesine / Q000494:pharmacology; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004347:Drug Interactions; D005910:Glioma; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D000318:Adrenergic beta-Agonists; D000928:Antidepressive Agents; D000963:Antimetabolites; D000975:Antioxidants; D018696:Neuroprotective Agents; D010726:Phosphodiesterase Inhibitors; D019328:Buthionine Sulfoximine; D003994:Bucladesine; D000242:Cyclic AMP; D005978:Glutathione; D007545:Isoproterenol; D015056:1-Methyl-3-isobutylxanthine